Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral Pathologies
NCT ID: NCT07332234
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2025-12-01
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optic Nerve Ultrasound in Severe Traumatic Injury
NCT02618226
Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging for Predicting the Outcomes of Intracranial Dissecting Aneurysm
NCT07335029
Orbital Artery Doppler Ultrasound in Brain Death
NCT06229782
Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy
NCT00697528
AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction
NCT06766422
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Investigators Principal Investigator (1): Bogdan PAVEL, MD, PhD, DESA, "Dr. Victor Babes" Clinical Hospital of Infectious and Tropical Diseases.
Principal Investigator (2): Sebastian ISAC, MD, PhD, DESA, Fundeni Clinical Institute Principal Investigator (3): Prof. Gabriela DROC, M.D., Ph.D., Fundeni Clinical Institute
Study Design Study Type: Observational Estimated Number of Participants: 200 participants Primary Purpose: Evaluation Actual Study Start Date: December 1st, 2025 Estimated Primary Completion Date: December 1st, 2027 Estimated Study Completion Date: December 1st, 2027
Groups and Interventions
Group 1: Infectious Pathology Group
Patients admitted with suspected meningitis or encephalitis will undergo the following investigations:
Assessment of consciousness using validated scales (GCS, RASS).
Optic nerve ultrasound to measure the optic nerve sheath diameter (ONSD), performed according to the following protocol:
The patient is positioned supine at a 20-30° incline. A linear probe (9-10 MHz; depth=40 mm; focus=30 mm) is used. The optic nerve must be visible at least 6 mm posterior to the retina. The retinal artery is identified. The diameter of the optic nerve is measured 3 mm posterior to the retina in both the transverse and sagittal planes; the reported value is the mean of the two measurements.
Measurements are performed independently by two examiners. Transcranial Doppler (TCD) to determine the pulsatility index of the middle cerebral artery.
Computed tomography (CT) to exclude intracranial hypertension. Lumbar puncture with measurement of cerebrospinal fluid (CSF) opening pressure. Blood sampling for C-reactive protein (CRP) and neuron-specific enolase (NSE) levels.
Daily Monitoring During Hospitalization:
Daily assessment of consciousness (GCS, RASS) at 09:00. Daily optic nerve ultrasound at 09:00 following the protocol described above. Daily TCD examination of the middle cerebral artery at 09:10. CT scan if clinical signs of intracranial hypertension develop or if there is a sudden decline in GCS of \>3 points.
Repeat lumbar puncture with CSF pressure measurement at 72 hours and 7 days after admission.
Blood sampling for CRP, NSE, and total antioxidant capacity at admission, 72 hours, and 7 days.
Group 2: Patients With Non-Infectious Neurological Pathology
Patients admitted with suspected stroke (CVA), brain tumors, or metabolic encephalopathy will undergo the following investigations:
Assessment of consciousness using validated scales (GCS, RASS).
Optic nerve ultrasound to measure the optic nerve sheath diameter (ONSD), performed according to the following protocol:
The patient is positioned supine at a 20-30° incline. A linear probe (9-10 MHz; depth=40 mm; focus=30 mm) is used. The optic nerve must be visible at least 6 mm posterior to the retina. The retinal artery is identified. The diameter of the optic nerve is measured 3 mm posterior to the retina in both the transverse and sagittal planes; the reported value is the mean of the two measurements.
Measurements are performed independently by two examiners. Transcranial Doppler (TCD) to determine the pulsatility index of the middle cerebral artery.
Computed tomography (CT) to exclude intracranial hypertension. Lumbar puncture with measurement of cerebrospinal fluid (CSF) opening pressure. Blood sampling for C-reactive protein (CRP) and neuron-specific enolase (NSE) levels.
Daily Monitoring During Hospitalization:
Daily assessment of consciousness (GCS, RASS) at 09:00. Daily optic nerve ultrasound at 09:00 following the standardized measurement protocol.
Daily TCD examination at 09:10 to assess the middle cerebral artery pulsatility index.
CT scan if signs of intracranial hypertension appear or if the GCS decreases abruptly by \>3 points.
Lumbar puncture with CSF pressure measurement at 72 hours and 7 days after admission (if applicable).
Blood sampling for CRP and NSE levels at 72 hours and 7 days after admission.
General Objectives
1. Primary Objectives:
To evaluate the sensitivity and specificity of optic nerve ultrasound in the assessment of cerebral inflammation and cerebral edema.
To establish threshold values for diagnosing intracranial hypertension, according to the specific pathology.
To correlate the optic nerve diameter with the patients' clinical condition.
2. Secondary Objectives:
28-day mortality Quality of life assessment on day 28 Rate of local and systemic complications
Inclusion Criteria:
* Patients admitted into one of the specified wards of the involved hospitals
* Patients aged 18-60 years
* Suspected meningitis, encephalitis, stroke or cerebral tumors
Exclusion Criteria:
* Age under 18 years or over 60 years old
* Ocular lesions preventing ocular ultrasound (palpebral infections, cornean erosions, glaucoma, trauma)
* Conditions preventing lumbar puncture (coagulation disorders, epidural abscesses, local infections)
All data is collected and stored electronically, using a tabular Excel file shared by all investigators.
Ethical Considerations: For this study, we request deferred consent and invoke the emergency consent procedure for medical research, in accordance with Article 6, paragraph 4 of the WMO. This approach is justified for the following reasons:
Patients admitted to infectious disease, neurology, or intensive care units often lack the capacity to provide informed consent. Under the Medical Treatment Act (WGBO), individuals who may serve as legal representatives include: a pre-designated representative, a spouse, a registered or other life partner, a parent or child, a sibling, and, in some cases, a court-appointed guardian. However, legal representatives are frequently not present when patients are admitted to the ICU or when the inclusion criteria are met. Moreover, obtaining informed consent from a legal representative requires sufficient time for them to review and consider the information provided. In the acute phase of admission-particularly in the ICU-legal representatives are naturally focused on the patient's clinical status rather than participation in research.
Procedures for Obtaining Consent Informed consent will be requested from the legal representative as soon as possible and no later than 48 hours after the inclusion criteria are met. If feasible, informed consent will be obtained in advance.
If informed consent from the legal representative is not obtained within 48 hours, or if the representative refuses participation within this period, the patient will be excluded and all collected data will be removed from the study.
The legal representative will receive both oral and written information, provided either in person or via telephone and email. Written informed consent may be returned by email within 12 hours of receiving the information, but always within the 48-hour window following inclusion.
Consent received by email must subsequently be confirmed with a signed paper form as soon as possible, and no later than 48 hours after the emailed confirmation.
Retrospective Consent From the Patient A second informed consent procedure will be conducted retrospectively once the patient regains capacity and is able to adequately understand the situation. At that time, the study information will be provided directly to the patient, and written informed consent will be requested and signed by both the patient and the executive investigator. If the patient declines participation, all data collected up to that point will be permanently deleted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Infectious Pathology Group
Patients admitted into the hospital with suspected meningitis or encephalitis
Optic Nerve Sheath Diameter
Ultrasonographic measurement of the optic nerve sheath diameter
Non-Infectious Pathology Group
Patients admitted into the hospital with suspected stroke or cerebral tumors (non-infectious pathology)
Optic Nerve Sheath Diameter
Ultrasonographic measurement of the optic nerve sheath diameter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Optic Nerve Sheath Diameter
Ultrasonographic measurement of the optic nerve sheath diameter
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 18-60 years
* Suspected meningitis, encephalitis, stroke or cerebral tumors
Exclusion Criteria
* Ocular lesions preventing ocular ultrasound (palpebral infections, cornean erosions, glaucoma, trauma)
* Conditions preventing lumbar puncture (coagulation disorders, epidural abscesses, local infections)
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institutul Clinic Fundeni
OTHER
Spitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bogdan Pavel
MD, PhD, DESA
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bogdan Pavel, MD, PhD, DESA
Role: PRINCIPAL_INVESTIGATOR
"Dr. Victor Babeș" Clinical Hospital for Infectious and Tropical Diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundeni Clinical Institute
Bucharest, Bucharest, Romania
"Dr. Victor Babeș" Clinical Hospital for Infectious and Tropical Diseases
Bucharest, Bucharest, Romania
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18261-14/10/2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.